Overview

A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Status:
Recruiting

Trial end date:
2023-03-20

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Ustekinumab